CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Thumbnail
Name:
964.full.pdf
Size:
800.1Kb
Format:
PDF
Request:
Main article
Download
Authors
Hills, Robert
Burnett, Alan
Lucas, Claire
Scott, Laura
Carmell, Natasha
Holcroft, Alison
Clark, Richard
Affiliation
University of Liverpool, Royal Liverpool University hospital, University of Cardiff
Publication Date
2018-04-27

Metadata
Show full item record
Abstract
Key Points PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.
Citation
Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K. & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood advances, 2(9), 964-8.
Publisher
American Society for Hematology
Journal
Blood Advances
URI
http://hdl.handle.net/10034/622167
DOI
10.1182/bloodadvances.2017013615
Additional Links
http://www.bloodadvances.org/content/2/9/964/tab-article-info
Type
Article
Language
en
EISSN
2473-9529
2473-9537
Collections
http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/